A*02:01/Human Survivin (96-104) – LTLGEFLKL – Peptide of survivin

Survivin protein

Survivin, also called BIRC5 , is a member of the apoptosis inhibitor protein family containing a baculovirus domain. Survivin is overexpressed in most human cancers but rarely express in normal differentiated adult tissues. Survivin protein inhibits caspase activation leading to negative regulation of cell death and promote cell proliferation. Survivin localizes in G2/M phase in cell cycle and interacts with tubulin during mitosis. It has been demonstrated that Survivin expression seems to be regulated by the tumor protein p53. Human Survivin contains HLA-A*02:01 binding motifs.

Applications of A*02:01/Human Survivin (96-104)

A*02:01/Human Survivin (96-104) HLA-A*02:01-restricted can be recognized by cytotoxic T lymphocytes on MHC I. Therefore, A*02:01/Human Survivin (96-104) may serve as a target for therapeutics CTL responses and for anticancer immunotherapeutic strategies. A*02:01/Human Survivin (96-104) is used to stimulate CTL responses in peripheral blood mononuclear cells (PBMCs). Then, ELISPOT assay is used to quantify peptide epitope specificity and IFN-γ releasing effector cells. A*02:01/Human Survivin (96-104) have shown spontaneous T-cell reactivity in chronic lymphatic leukemia and in melanoma. A*02:01/Human Survivin (96-104) has also demonstrated the ability to induce CTL responses in lung cancer and may serve for developing cancer vaccines.


Technical specification

A*02:01/Human Survivin (96-104) peptide buy Sequence : LTLGEFLKL
A*02:01/Human Survivin (96-104) peptide synthesis MW : 1033,26 g/mol (C50H84N10O13)
A*02:01/Human Survivin (96-104) price Purity : > 95%
Peptide Library synthesis Counter-Ion : TFA Salts (see option TFA removal)
Peptide library synthesis A*02:01/Human Survivin (96-104) Delivery format : Freeze dried in propylene 2mL microtubes
peptide solubility guidelines Peptide Solubility Guideline
buy peptide price Bulk peptide quantities available



Product catalog Size Price € HT Price $ HT
SB055-1MG 1 mg 88 110
SB055-5MG 5 mg 308 385
SB055-10MG 10 mg 522 653
SB055-50MG 50 mg 1815 2268



1- Altieri D. C. Nat Rev Cancer. 3(1):46-54 (2003)
Validating survivin as a cancer therapeutic target


Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?

2- Ambrosini G., Adida C. and Altieri D. C. Nat Med. 3(8):917-921 (1997)
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma


Inhibitors of programmed cell death (apoptosis) aberrantly prolonging cell viability may contribute to cancer by facilitating the insurgence of mutations and by promoting resistance to therapy. Despite the identification of several new apoptosis inhibitors related to bcl-2 or to the baculovirus IAP gene, it is not clear whether apoptosis inhibition plays a general role in neoplasia. Here, we describe a new human gene encoding a structurally unique IAP apoptosis inhibitor, designated survivin. Survivin contains a single baculovirus IAP repeat and lacks a carboxyl-terminal RING finger. Present during fetal development, survivin is undetectable in terminally differentiated adult tissues. However, survivin becomes prominently expressed in transformed cell lines and in all the most common human cancers of lung, colon, pancreas, prostate and breast, in vivo. Survivin is also found in approximately 50% of high-grade non-Hodgkin’s lymphomas (centroblastic, immunoblastic), but not in low-grade lymphomas (lymphocytic). Recombinant expression of survivin counteracts apoptosis of B lymphocyte precursors deprived of interleukin 3 (IL-3). These findings suggest that apoptosis inhibition may be a general feature of neoplasia and identify survivin as a potential new target for apoptosis-based therapy in cancer and lymphoma.

3- Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C. and Altieri D. C. Nature. 396(6711):580-584 (1998)
Control of apoptosis and mitotic spindle checkpoint by surviving


Progression of the cell cycle and control of apoptosis (programmed cell death) are thought to be intimately linked processes, acting to preserve homeostasis and developmental morphogenesis. Although proteins that regulate apoptosis have been implicated in restraining cell-cycle entry and controlling ploidy (chromosome number), the effector molecules at the interface between cell proliferation and cell survival have remained elusive. Here we show that a new inhibitor of apoptosis (IAP) protein, survivin, is expressed in the G2/M phase of the cell cycle in a cycle-regulated manner. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle in a specific and saturable reaction that is regulated by microtubule dynamics. Disruption of survivin-microtubule interactions results in loss of survivin’s anti-apoptosis function and increased caspase-3 activity, a mechanism involved in cell death, during mitosis. These results indicate that survivin may counteract a default induction of apoptosis in G2/M phase. The overexpression of survivin in cancer may overcome this apoptotic checkpoint and favour aberrant progression of transformed cells through mitosis.

4- Duffy M. J., O’Donovan N., Brennan D. J., Gallagher W. M. and Ryan B. M. Cancer Lett. 249(1):49-60 (2007)
Survivin: A promising tumor biomarker


Survivin is a 16.5 kDa protein overexpressed in almost all malignancies but rarely detected in normal differentiated adult tissues. Functionally, survivin has been shown to inhibit apoptosis, promote cell proliferation and enhance angiogenesis. Consistent with its role in these processes, survivin has been shown to play a key role in cancer progression. Because of the large difference in expression between normal and malignant tissue and its causal role in cancer progression, survivin is currently undergoing intensive investigation as a potential tumor marker. Emerging data suggests that measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis in multiple cancer types and predict response to diverse anti-cancer therapies. These preliminary findings on the diagnostic, prognostic and predictive potential of survivin should now be confirmed in large prospective trials. Furthermore, assays for the measurement of survivin should be simplified, standardized and evaluated in external quality assurance schemes.

5- Andersen M. H., Pederson L. O., Becker J. C. and thor Straten P. American Association for Cancer Research; 61(3):869-872 (2001)
Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients


During the last decade, a large number of human tumor-associated antigens have been identified that are recognized by CTLs in a MHC-restricted fashion. The apoptosis inhibitor protein survivin is overexpressed in most human cancers, and inhibition of its function results in increased apoptosis. Therefore, this protein may serve as a target for therapeutic CTL responses. Here, using CTL epitopes deduced from survivin, we describe specific T-cell reactivity against this antigen in peripheral blood from chronic lymphatic leukemia patients and in tumor-infiltrated lymph nodes from melanoma patients by ELISPOT analysis. CTL responses against two survivin-deduced peptide epitopes were detected in three of six melanoma patients and three of four chronic lymphatic leukemia patients. No T-cell reactivity was detected in peripheral blood lymphocytes from six healthy controls. Thus, survivin may serve as an important and widely applicable target for anticancer immunotherapeutic strategies.